Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for allegedly making false and misleading statements regarding its business performance and financial guidance during the Class Period from November 7, 2024, to July 8, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [5]. - Defendants allegedly overstated the demand for RxSight's products, which resulted in the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [5]. - The misleading statements made by the defendants about RxSight's business operations and prospects caused investors to suffer damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased RxSight securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must move the Court by September 22, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. alleging securities fraud that negatively impacted investors between November 7, 2024, and July 8, 2025 [1][2] Group 1: Allegations of Fraud - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2] - It is alleged that the defendants overstated the demand for RxSight's products [2] - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [2] - Positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and has been recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of RxSight, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical issues affecting the company's performance during the specified class period [1][2]. Group 1: Allegations Against RxSight, Inc. - The complaint alleges that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [1]. - It is claimed that the defendants overstated the demand for RxSight's products [1]. - The lawsuit suggests that RxSight is unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [1]. - Positive statements made by the defendants about the company's business and prospects are described as materially misleading and lacking a reasonable basis [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as November 7, 2024, to July 8, 2025 [1]. - Shareholders are encouraged to register for the class action by the deadline of September 22, 2025, to potentially be appointed as lead plaintiffs [2]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. Group 3: Gross Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and engage in good corporate citizenship [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that artificially inflated stock prices [3].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, specifically related to undisclosed challenges in product adoption and subsequent revenue forecast cuts [1][2][4]. Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Financial Performance and Stock Impact - The company experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors during a period when RxSight promoted strong sales [4]. - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell again by about 38%, from $12.79 to $7.95 per share [6].

Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Financial Performance - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in Light Delivery Device (LDD) sales, light adjustable intraocular lenses utilization, and overall revenue [3]. - The company lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [3]. - Following the announcement, RxSight's stock price fell by $4.84 per share, or 37.84%, closing at $7.95 per share on July 9, 2025 [3]. Legal Context - Investors who purchased or acquired RxSight securities during the Class Period have until September 22, 2025, to request appointment as Lead Plaintiff [2]. - The lawsuit is being handled by Pomerantz LLP, a firm recognized for its expertise in corporate, securities, and antitrust class litigation [4].

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines following the disclosure of poor financial results [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that RxSight overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of poor financial results led to a nearly 38% drop in the price of RxSight's stock [5].

Group 1 - A lawsuit has been filed against RxSight, Inc. and certain senior executives for potential violations of federal securities laws [1][2] - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities [2] - The case is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596 [2] Group 2 - RxSight manufactures and sells light adjustable intraocular lenses used in cataract surgery, with its main product being the Light Adjustable Lens (LAL) [3] - The company has faced "adoption challenges" and a slowdown in LAL utilization, which was first noted in 2024 [4] Group 3 - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price decline of approximately 38%, from $26.12 to $16.21 per share [5] - On July 8, 2025, the company further reduced its revenue forecast, resulting in another 38% decline in stock price, from $12.79 to $7.95 per share [6]

Core Viewpoint - A class action has been filed against RxSight, Inc. for allegedly misleading investors about product demand and financial performance during the specified period [1][2]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) for cataract surgery in the U.S. [1]. Allegations - The complaint alleges that RxSight failed to disclose significant adoption challenges and structural issues leading to declines in sales and utilization of its products [2]. - It is claimed that the company overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [2]. Financial Performance - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in Light Delivery Device (LDD) sales, LAL utilization, and overall revenue [3]. - The company lowered its full year 2025 guidance by approximately $42.5 million at the midpoint, with the CEO citing adoption challenges as a primary reason for the sales stall [3]. - Following this announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025 [3].

PHILADELPHIA, July 25, 2025 /PRNewswire/ -- Berger Montague PC, a national securities litigation law firm announces it is investigating potential securities fraud claims involving RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST), following the recent filing of a federal securities class action lawsuit.The lawsuit alleges that Defendants failed to disclose to investors that: (1) RxSight was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization; (2 ...

Core Viewpoint - Edelson Lechtzin LLP is investigating securities fraud claims against RxSight, Inc. for misleading statements regarding its business and financial performance during the specified Class Period [1][4]. Company Background - RxSight, Inc. is a commercial-stage medical technology company that specializes in the research, development, manufacturing, and marketing of light-adjustable intraocular lenses (LAL) used in cataract surgery [3]. Securities Fraud Claims - The class action complaint alleges that RxSight made materially false and misleading statements, failing to disclose declines in product sales and utilization, and overstating demand for its intraocular lens products [4]. - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [4]. Financial Performance - On July 9, 2025, RxSight reported significant declines in sales of its Light Delivery Device (LDD), usage of its light-adjustable intraocular lenses (LALs), and total revenue, leading to a reduction in its Full Year 2025 guidance by approximately $42.5 million [5]. - Following this disclosure, RxSight's stock price fell by $4.84 per share, or 37.8%, closing at $7.95 per share on July 9, 2025 [5].